Endometrial Cancer Clinical Trials

240 recruitingLast updated: June 17, 2026

There are 240 actively recruiting endometrial cancer clinical trials across 48 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include Houston, Texas, United States, New York, New York, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Endometrial Cancer Trials at a Glance

240 actively recruiting trials for endometrial cancer are listed on ClinicalTrialsFinder across 6 cities in 48 countries. The largest study group is Phase 2 with 68 trials, with the heaviest enrollment activity in Houston, New York, and Boston. Lead sponsors running endometrial cancer studies include AstraZeneca, Memorial Sloan Kettering Cancer Center, and Dana-Farber Cancer Institute.

Browse endometrial cancer trials by phase

Treatments under study

About Endometrial Cancer Clinical Trials

Looking for clinical trials for Endometrial Cancer? There are currently 220 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Endometrial Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Endometrial Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 240 trials

Recruiting
Phase 1

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

Endometrial CancerTesticular CancerPlatinum Resistant Ovarian Cancer
Context Therapeutics Inc.156 enrolled14 locationsNCT06515613
Recruiting
Phase 1

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

Ovarian CancerEndometrial CancerGerm Cell Tumor+2 more
Xencor, Inc.282 enrolled18 locationsNCT06276491
Recruiting
Not Applicable

Menstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome

Endometrial CancerLynch SyndromeEarly Detection of Cancer+1 more
Jessica D. St. Laurent, MD25 enrolled1 locationNCT07220239
Recruiting
Phase 3

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

Endometrial CancerMalignant Solid Tumour
AstraZeneca800 enrolled317 locationsNCT07044336
Recruiting
Phase 2

PROton Therapy for Post Surgical Treatment of GYNecologic Cancer

Cervical CancerEndometrial CancerUterine Cancer
Abramson Cancer Center at Penn Medicine25 enrolled3 locationsNCT05758688
Recruiting
Phase 2

A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer

Endometrial Cancer
Memorial Sloan Kettering Cancer Center75 enrolled7 locationsNCT07209449
Recruiting
Phase 2

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

Endometrial Cancer
Canadian Cancer Trials Group393 enrolled110 locationsNCT05640999
Recruiting
Phase 1

A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)

Advanced Relapsed or Refractory Germ Cell TumoursAdvanced Relapsed or Refractory Endometrial CancerAdvanced Relapsed or Refractory Ovarian Cancer
Boehringer Ingelheim187 enrolled13 locationsNCT07306559
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations

Non-small Cell Lung Cancer (NSCLC)Ovarian CancerEndometrial Cancer+4 more
Shenzhen Ionova Life Sciences Co., Ltd.178 enrolled1 locationNCT07610798
Recruiting
Phase 1

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Breast CancerOvarian CancerCervical Cancer+6 more
Regor Pharmaceuticals Inc.63 enrolled4 locationsNCT07524322
Recruiting
Phase 2

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Breast CancerColorectal, CancerEsophageal Cancer+9 more
Jazz Pharmaceuticals200 enrolled28 locationsNCT06695845
Recruiting
Phase 1

A Phase 1 Study of the Safety and Tolerability of CTX-10726

Endometrial CancerRenal Cell Carcinoma (RCC)Hepatocellular Carcinoma (HCC)+1 more
Compass Therapeutics70 enrolled5 locationsNCT07419841
Recruiting
Phase 1

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

Endometrial Cancer
M.D. Anderson Cancer Center21 enrolled1 locationNCT05819892
Recruiting
Phase 2

TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd EC

Endometrial Cancer
Fudan University10 enrolled1 locationNCT06914297
Recruiting
Phase 1

A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

Endometrial CancerHER2-low Breast CancerHR Positive/HER-2 Negative Breast Cancer+2 more
Cogent Biosciences, Inc.90 enrolled2 locationsNCT07383506
Recruiting
Phase 1Phase 2

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

Ovarian CancerEndometrial CancerLung Adenocarcinoma+1 more
AstraZeneca506 enrolled60 locationsNCT05797168
Recruiting

Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy

Ovarian CancerCervical CancerEndometrial Cancer+5 more
Aesculap AG132 enrolled2 locationsNCT06024109
Recruiting
Phase 3

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

Endometrial CancerRecurrent or Progressive Endometrial Cancer
Genmab660 enrolled81 locationsNCT07166094
Recruiting
Phase 1Phase 2

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab884 enrolled66 locationsNCT05579366
Recruiting
Phase 3

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Endometrial Cancer
Merck Sharp & Dohme LLC1,123 enrolled253 locationsNCT06952504